In the DESTINY Breast-04 trial [19], T-Dxd was evaluated in 557 patients (494 hormone receptor [HR]-positive and 63 triple-negative breast cancer [TNBC]) with inoperable or metastatic low HER2 breast cancer who had received one or two prior lines of chemotherapy. Here, ERBB2 is linked to triple-negative breast carcinoma.